hUMSC-Exosomes suppress TREM1-p38 MAPK signaling via HMGB1-dependent mechanisms to reprogram microglial function and promote neuroprotection in ischemic stroke
Zhang Z., Ji R., Liu Z., Jiang Z., Chu M., Wang Y.
Animal Study on Stroke Research, Neuroinflammation, Chronic Inflammation, published in J Nanobiotechnology (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- J Nanobiotechnology (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40830888
- PMCID
- PMC12363081
- DOI
- 10.1186/s12951-025-03652-z
- Citations
- 3
Abstract (original English)
Background Ischemic stroke induces profound neuroinflammation, where microglial activation exacerbates secondary brain injury. Human umbilical mesenchymal stem cell-derived exosomes (hUMSC-Exos) exhibit therapeutic potential, but their mechanisms in modulating microglial responses remain incompletely understood. Results Following intranasal administration, hUMSC-Exos selectively accumulated in ischemic brain regions and were internalized by microglia. In transient middle cerebral artery occlusion (tMCAO) mice, hUMSC-Exos improved neurological outcomes, reduced neuronal apoptosis, and promoted a sustained shift in microglial polarization toward an anti-inflammatory phenotype-evidenced by suppressed pro-inflammatory and elevated anti-inflammatory markers in peri-infarct areas. These effects were replicated in LPS/IFN-γ-stimulated primary microglia and BV2 cells. Microglia-specific RNA sequencing revealed that hUMSC-Exos reversed tMCAO-induced pro-inflammatory and migratory transcriptional programs, concurrently suppressing p38 MAPK while activating immunoregulatory pathways. TREM1 emerged as a critical node, with hUMSC-Exos downregulating its expression in microglia; pharmacological TREM1 inhibition (LP17) synergistically augmented the suppression of microglial activation, migration, and proliferation. Mechanistically, hUMSC-Exos attenuated NF-κB/p38 MAPK signaling, with TREM1 fu
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level AMeta-analysisEurope PMC
Stem cell therapy for ischemic stroke: neuroimaging approaches and evidence from a systematic review
Meta-analysis on Stroke Research, published in Front Neurol (2026) — summary generated from the PubMed abstract.
- 2026
Front Neurol - Level AMeta-analysisEurope PMC
Efficacy and safety of stem cell therapy for myocardial infarction and heart failure: an updated systematic review and meta-analysis of randomized controlled trials
Meta-analysis with a reported sample of 3345 on Cardiovascular Disease, Stroke Research, published in Syst Rev (2026) — summary generated from the PubMed abstract.
- 2026
- n = 3345
Syst Rev - Level AMeta-analysisEurope PMC
Safety and Efficacy of Transendocardial Stem Cells Therapy in Chronic Ischemic Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Meta-analysis on Cardiovascular Disease, Stroke Research, published in Curr Cardiol Rev (2025) — summary generated from the PubMed abstract.
- 2025
Curr Cardiol Rev - Level AMeta-analysisEurope PMC
Efficacy and Potential Mechanisms of Umbilical Cord-Derived Mesenchymal Stem Cells in the Treatment of Ischemic Stroke in Animal Models: A Meta-Analysis
Meta-analysis on Stroke Research, published in CNS Neurosci Ther (2025) — summary generated from the PubMed abstract.
- 2025
CNS Neurosci Ther5 citations - Level AMeta-analysisPubMed
The inconclusive superiority debate of allogeneic versus autologous MSCs in treating patients with HFrEF: a systematic review and meta-analysis of RCTs.
Meta-analysis with a reported sample of 1184 on Cardiovascular Disease, Stroke Research, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.
- 2025
- n = 1184
Stem Cell Res Ther2 citations - Level ASystematic ReviewEurope PMC
In vitro and In vivo Studies on Mesenchymal Stem Cells for Ischemic Stroke Therapy: A Scoping Review of The Therapeutic Effect
Systematic Review on Stroke Research, published in Stem Cells Cloning (2025) — summary generated from the PubMed abstract.
- 2025
Stem Cells Cloning